Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves New Drug for Parkinson’s Disease


Parkinson's Disease

The drug is designed to complement levodopa/carbidopa during periods of decreased medication effectiveness and increased symptom severity, known as an “off” episode.

Share this!

March 23, 2017 | by Sarah Hand, M.Sc.

Newron Pharmaceuticals’ Xadago (safinamide) has been approved by the US Food and Drug Administration (FDA) as an add-on medication for patients with Parkinson’s disease. The drug is designed to complement levodopa/carbidopa during periods of decreased medication effectiveness and increased symptom severity, known as an “off” episode.

“Parkinson's is a relentless disease without a cure,” said Dr. Eric Bastings, deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. “We are committed to helping make additional treatments for Parkinson's disease available to patients.”

The FDA’s decision to approve the treatment was informed by a clinical trial of Xadago involving 645 patients. All patients in the trial were taking levodopa, however they were also experiencing an “off” time with an increase in symptoms such as tremor and difficulty walking.

Patients in the trial treated with Xadago showed a reduction of Parkinson’s symptoms during their “on” time, and a reduction in the duration of “off” time, compared to a placebo. An additional clinical trial involving 549 participants, showed similar results in terms of more productive “on” times with better scores on tests of motor function.

According to statistics from the National Institutes of Health (NIH), around 50,000 people in the US are diagnosed with Parkinson’s disease every year. Currently, approximately 1 million Americans suffer from the degenerative disorder.

The disease results in the death of dopamine-producing neurons in the brain. Dopamine is involved in transmitting signals throughout the brain, and allowing the muscles to move in a controlled and coordinated manner.

Levodopa is a first-line treatment for the management of Parkinson’s disease symptoms. It is converted into dopamine in the body, and acts as a replacement for the natural dopamine lost due to cell death.

Symptoms of Parkinson’s disease generally do not develop until age 60, although some patients experience earlier-onset. The cause of Parkinson’s disease is unknown, and there is no cure for the neurological disorder.

Keywords: FDA, Drug Approvals, Parkinson's Disease


Share this with your colleagues!

Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News

FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News

Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News


What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation


Technology Solutions for Late Phase Research: Optimising Real World Data Assets

Serialization for Late Starters – With Live Industry Research Results

Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse

The New Gold Standards of IRT Delivery for Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.